ONCOLYTICS BIOTECH FILES ROUTINE 6-K, ATTACHES PRESS RELEASE
Ticker: ONCY · Form: 6-K · Filed: Jan 9, 2024 · CIK: 1129928
| Field | Detail |
|---|---|
| Company | Oncolytics Biotech INC (ONCY) |
| Form Type | 6-K |
| Filed Date | Jan 9, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, foreign-issuer, press-release
TL;DR
**This 6-K is just a formality; check the attached press release for actual news.**
AI Summary
Oncolytics Biotech Inc., a pharmaceutical preparations company, filed a 6-K on January 9, 2024, indicating it is a foreign private issuer. This routine filing, under Commission File Number 001-38512, primarily serves to attach a press release as Exhibit 99.1. For investors, this filing itself doesn't contain new material financial or operational information, but rather points to an external press release that would contain any substantive updates, making it important to review that linked document for actual news.
Why It Matters
This filing is a procedural update for a foreign private issuer and signals that any new material information would be found in the attached press release, which investors should seek out.
Risk Assessment
Risk Level: low — This 6-K filing is purely administrative and does not introduce new risks or material information itself.
Analyst Insight
An investor should locate and review the attached Press Release (Exhibit 99.1) to understand any actual material news or updates from Oncolytics Biotech Inc., as this 6-K itself is purely administrative.
Key Players & Entities
- Oncolytics Biotech Inc. (company) — the registrant and foreign private issuer
- January 2024 (date) — the month for which the report is filed
- 001-38512 (other) — the Commission File Number for Oncolytics Biotech Inc.
- 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (other) — the address of principal executive offices
- Exhibit 99.1 (other) — the attached press release
FAQ
What is the primary purpose of this specific 6-K filing by Oncolytics Biotech Inc.?
The primary purpose of this 6-K filing, dated January 9, 2024, is to submit a 'Report of Foreign Private Issuer' and to furnish a Press Release as Exhibit 99.1, as indicated in the 'EXHIBIT NUMBER DESCRIPTION' section.
Under which SEC Act is Oncolytics Biotech Inc. filing this report?
Oncolytics Biotech Inc. is filing this report pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, as stated in the Form 6-K document.
What is the Commission File Number for Oncolytics Biotech Inc.?
The Commission File Number for Oncolytics Biotech Inc. is 001-38512, as specified in the filing.
Does Oncolytics Biotech Inc. file annual reports under Form 20-F or Form 40-F?
Oncolytics Biotech Inc. indicates by check mark that it files annual reports under cover Form 20-F, not Form 40-F.
What is the business address listed for Oncolytics Biotech Inc. in this filing?
The business address listed for Oncolytics Biotech Inc. is Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2024-01-09 08:44:10
Filing Documents
- form6kpatandrews.htm (6-K) — 18KB
- oncypatandrews.htm (EX-99.1) — 16KB
- 0001129928-24-000004.txt ( ) — 35KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date January 9, 2024 Kirk Look Chief Financial Officer